How many investments has SR One Capital Management made?

SR One Capital Management has 76 tracked investments, 18 of which have exited, including 7 dated in the last 24 months.

What stage does SR One Capital Management invest at?

SR One Capital Management invests at the Seed, Series A, Series B stages.

What sectors does SR One Capital Management focus on?

SR One Capital Management focuses on Biotech, Healthtech, Medical Devices.

Where is SR One Capital Management located?

SR One Capital Management is headquartered in Redwood City, US.

Who does SR One Capital Management co-invest with?

SR One Capital Management most often shares deals with OrbiMed, RA Capital, New Enterprise Associates (NEA), among 100 tracked co-investors.

What size deals does SR One Capital Management back?

Across 16 deals with disclosed amounts, SR One Capital Management has joined rounds of $13M – $220M (median $57.5M).

SR One Capital Management

Venture capitalActively deploying

Redwood City · Seed–Series B · 30 people tracked

Also known as SR ONE CAPITAL MANAGEMENT, LP

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into SR One Capital Management

Each arrow is one introduction. Sign up to fill in the first one.

1,132 people can intro you to Rajeev

Ask Akshay Patel to introduce you to Rajeev Dadoo

You →Akshay · together at Synapse Investment →Rajeev

806 people can intro you to Jake

Ask Jamie Chen to introduce you to Jake Bauer

You →Jamie · together at Phoenix Tissue Repair, Inc. →Jake

739 people can intro you to Laetitia

Ask Sam Okafor to introduce you to Laetitia Schwab

You →Sam · together at Draig Therapeutics →Laetitia

Amit Shah647 people can intro you
Mike Farrell633 people can intro you
Brian Gallagher453 people can intro you

Your email: who you already know at SR One Capital Management, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the SR One Capital Management team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

SR One is a biotechnology venture capital firm that backs companies translating novel science into medicines. It uses a 'back-and-build' approach, focusing on companies with strong fundamentals, a clearly defined development pathway, and novel approaches to treating disease. With an investing team based in West Coast biotech hubs in the USA and in London, UK, the firm leverages its transatlantic footprint to act as a strategic partner, offering geographic reach and regional expertise to source opportunities and provide real-time business support to portfolio companies.

Invests inBiotech Healthtech Medical Devices Asia-Pacific Europe Global North America Redwood City United Kingdom United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Series B

Redwood City, California, US

Instruments

Equity

Founded

1985

Last 12 months

4 investments

AUM

$2.4B

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 30 people

from the firm's website & curated & public directories

Mike Farrell· Chief Executive Officer and Co-Founder· Cambridge, Massachusetts, United Statesin

Managing Director at Spectrum Equity who commented on the firm's investment in and support of CyberCube.

Rajeev Dadoo· COO and Managing Partner· San Francisco Bay Areain

Rajeev Dadoo is COO and Managing Partner at SR One, which he joined in 2004, and is an alum of the Kauffman Fellows Program. He invests in therapeutics and healthcare-technology companies, drawing on operational and strategic experience from prior roles at GSK's Competitive Excellence group, Genentech, Bio-Rad Laboratories, and Genome Therapeutics, and he co-founded Unimicro Technologies. He holds a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University, and an MBA from the Wharton School.

rajeev@srone.com

Simeon J. George· Partner· Reedsburg, Wisconsin, United Statesin

Simeon J. George is CEO and co-founder of SR One Capital Management, a trans-Atlantic biotechnology venture capital firm that spun out of GSK in 2020 and maintains offices in the Bay Area and London. The firm invests in biotechnology companies with the aim of developing new medicines for areas of unmet medical need.

simeon@srone.com

Brian Gallagher· Partner· Boston, Massachusettsin 𝕏

Deborah Harland· Partner

Amit Shah· Principal· San Francisco Bay Areain 𝕏

Amit Shah is a Principal in SR One's London office, focusing on venture capital investments in biotech. Before joining SR One in early 2018, he held roles at GlaxoSmithKline spanning late-phase clinical development, global medical affairs, and early pipeline commercial strategy, and he is a board-certified-equivalent plastic surgeon specializing in microsurgical cancer reconstruction. He holds a B.A. in Medical Sciences, an M.A. in Neuroscience, and an M.D. from the University of Cambridge, and since 2020 has served on the venture capital panel for the BioInnovation Institute.

amit@srone.com

Jill Carroll· Operating Partner· East Coast (US)in

Jill Carroll is an Operating Partner at SR One, which she first joined in 2011, and manages several of the firm's investments. She holds a BS in Chemistry from Duke University and an MS in Biochemistry from Johns Hopkins University. Before SR One, she worked in strategy consulting and biotech corporate development, including at Dynavax Technologies.

jill@srone.com

Katarina Pance· Principal· San Francisco Bay Areain

Katarina Pance is a Principal at SR One, based in the San Francisco Bay Area, having joined the firm in 2023. She previously co-founded EpiBiologics, where she served as head of discovery biology, building on her graduate research on bispecific antibodies for extracellular protein degradation. She earned a BA in Biochemistry from the University of Pennsylvania and a PhD in Chemistry and Chemical Biology from UCSF, where she studied with Dr. Jim Wells, and was earlier a venture fellow at MPM Capital.

katarina@srone.com

Laetitia Schwab· Principal· Londonin

Laetitia Schwab is a Principal at SR One in the London office, joining in 2022. She previously worked in clinical development at Orchard Therapeutics, contributing to the delivery of the gene therapy Libmeldy for Marketing Authorisation, and has experience across early and late-phase clinical programs with expertise in gene therapy, neuroscience, and rare diseases. She holds a B.Sc in Medical Sciences from the University of Edinburgh, an MPhil in Translational Medicine and a Ph.D in Clinical Neuroscience from the University of Cambridge, and an MBA from INSEAD.

laetitia@srone.com

Amit Mehta· Venture Partner· San Francisco Bay Area

Amit Mehta is a Venture Partner at SR One, which he joined in 2024, and serves as COO and CBO at Dren Bio, an SR One portfolio company. He previously spent 18 years at Genentech, most recently as Vice President and Head of Business Development, where he worked on drug development, product strategy, and strategic partnerships. He holds a B.E. in Chemical Engineering from Bangalore University and a Ph.D. in Chemical Engineering from Pennsylvania State University.

sronemedia@sambrown.com

Chris Chai· Operating Partner· San Francisco Bay Areain

Chris Chai is an Operating Partner at SR One who advises portfolio companies on financing strategy, Wall Street engagement, and execution. He has more than 20 years of experience in biotech executive management and investment banking, having served as CFO at Principia Biopharma and MAP Pharmaceuticals and in treasury and investor relations at CV Therapeutics, and earlier held investment banking roles at JP Morgan. He holds a BS in Operations Research and Industrial Engineering from Cornell University.

sronemedia@sambrown.com

Jake Nunn· Partner· San Francisco Bay Areain

Jake Nunn is a Partner at SR One focusing on later-stage private and public biotech investments, with over 25 years in the life sciences industry as an investor, board director, research analyst, and investment banker. He was previously an investing partner at New Enterprise Associates (NEA) from 2006 to 2019, where he founded the firm's public healthcare investing practice, and earlier held roles at MPM Capital, Franklin Templeton Investments, and Alex. Brown & Sons. He holds an MBA from Stanford Graduate School of Business and a BA in Economics from Dartmouth College, and is a CFA charterholder.

jake@srone.com

Matthew R. Patterson· Venture Partner· San Francisco Bay Areain

Matthew R. Patterson is a Venture Partner at SR One Capital Management with over 30 years in the research, development, and commercialization of therapeutics. He co-founded Audentes Therapeutics in 2012 and served as its CEO until its 2020 acquisition by Astellas Pharma, and previously worked at Genzyme, BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine, as well as serving as an Entrepreneur-In-Residence at OrbiMed. He holds a Bachelor's degree in Biochemistry from Bowdoin College.

sronemedia@sambrown.com

Emily Warren· Venture Partner· Chicago, IL

Joined Sandbox Industries in 2023 as an Executive Assistant supporting internal team structure and event planning. Previously a special education teacher.

Jake Bauer· Venture Partner· San Francisco, Californiain

Jake Bauer is a Venture Partner at SR One who works with emerging clinical biotechnology companies. He previously served as Chief Business Officer of MyoKardia, which was acquired by Bristol Myers Squibb in 2020, and held earlier roles at Ablexis, Third Rock Ventures, Royalty Pharma, Endo Pharmaceuticals, and Putnam Associates. He holds a BS in Biology and BA in Economics from Duke University and an MBA from Harvard Business School.

sronemedia@sambrown.com

Alicia Hasson· Executive Administrative Support· San Francisco Bay Areain

Alicia Hasson joined SR One in 2024, working out of the San Francisco Bay Area office where she provides executive administrative support to Rajeev Dadoo, Jill Carroll, and Jake Nunn. She has 15 years of administrative experience in the biotech industry across large and small pharmaceutical companies. She studied Business Administration at City College of San Francisco.

Ann Ng· Finance Director· Londonin

Ann Ng is the Finance Director at SR One, based in the firm's London office, where she manages accounting, financial statements, and fund reporting while supporting the CFO on operations. She previously spent ten years at CITIC Capital Partners Limited in private equity fund management and operations. She holds a BA in Accounting & Finance from Curtin University of Technology and is a CPA (Australia).

sronemedia@sambrown.com

Briana Wilson· Senior Administrative Assistant· San Francisco Bay Area

Briana Wilson joined SR One in 2023 and provides administrative support to team members as well as assisting with event planning. She previously worked at Huntsman Gay Global Capital, where she handled administrative support, reception, and vendor relations. She holds a Bachelor of Science in Kinesiology from San Jose State University.

sronemedia@sambrown.com

Catalina Kazi· Legal and Compliance Counsel· San Francisco Bay Areain

Catalina Kazi is Legal and Compliance Counsel at SR One, which she joined in 2024. She previously worked for over five years as in-house counsel handling regulatory compliance at retail and institutional investment managers, and served as an attorney in the Securities Division of the Secretary of the Commonwealth of Massachusetts. She holds a B.A. in International Relations from Florida International University and a J.D. from Boston University School of Law, and is licensed to practice law in New York and Registered In-House Counsel in California.</bio_summary> <parameter name="investments">[]

sronemedia@sambrown.com

Frances Benson· Chief of Staff· San Francisco Bay Areain

Frances Benson joined SR One in 2020 as Chief of Staff, overseeing business functions such as operations, events, marketing, and PR. She previously worked at Sofinnova Investments, where she handled administrative support, reception, and vendor relations. She studied Interior Architecture and Design at the Academy of Arts University in San Francisco.

sronemedia@sambrown.com

Iqbal Mufti· Operating Partner· Londonin

Iqbal Mufti is an Operating Partner at SR One's London office, working on company creation, later-stage investments, and portfolio companies' industry engagement and partnering strategy. He previously worked at Hoffmann-La Roche, where he co-led the rare blood disorders portfolio strategy team and served as global Lifecycle Leader for Hemlibra (emicizumab). His background covers pharmaceutical product and portfolio strategy, late-stage development, global commercialization, business development, and M&A. He holds a BSc in Biotechnology from University College London and an MBA from Duke University's Fuqua School of Business.

sronemedia@sambrown.com

James Macadam· Chief Financial Officer· Londonin

James Macadam is Chief Financial Officer at SR One, based in the firm's London office, where he oversees financial matters and helps manage a range of the firm's operations. He joined SR One in 2019 after holding corporate finance and commercial roles at GlaxoSmithKline. He holds an MA in Geography from Oxford University, an MPhil in Polar Studies from Cambridge University, and an MBA from HEC Paris.</bio_summary> <parameter name="investments">[]

sronemedia@sambrown.com

Lyla Youssef· Associate· San Francisco Bay Areain

Lyla Youssef is an Associate at SR One, based in the San Francisco Bay Area, where she joined in 2024 with a background in biotechnology and therapeutics equities. She previously worked as an Associate Analyst covering therapeutics at Hudson Bay Capital, in biotech equity research as a Vice President at TD Cowen, and in equity research at Oppenheimer & Co., along with roles at Columbia University's Translational Therapeutics Accelerator and Columbia Tech Ventures. She holds a Ph.D. in Microbiology & Immunology from Columbia University and a B.A. in Biological Sciences and Economics from Cornell University.

lyla@srone.com

Mahesh Kudari· Senior Associate· Londonin

Mahesh Kudari is a Senior Associate at SR One's London office, which he joined in 2024. He previously served as VP Business Operations at Xap Therapeutics and Head of Clinical Development at Orchard Therapeutics, where he led cross-functional gene therapy development programs, and earlier held early clinical development and medical affairs roles at GSK. He holds a medical degree from University College London and an M.A. in Medical Sciences from the University of Cambridge, and has a background in diagnostic and interventional radiology.

mahesh@srone.com

Mary Mirt· Administrative Assistant· San Francisco Bay Areain

Mary Mirt joined SR One in 2025, where she provides administrative and office management support to team members. She previously held office management roles at Peakspan Capital and Pacific Lake Partners, handling vendor management and reception. She holds a Bachelor of Arts in Communication & Media Studies from CSU East Bay.

sronemedia@sambrown.com

Philip Habib· Leads Capital Partnering at SR One· Londonin

Philip Habib leads SR One's Capital Partnering effort and is based in London, with over 15 years of experience across venture capital, private equity, and real estate. He began his career in the Private Equity & Venture Capital group at Cambridge Associates advising institutional investors, and later worked at General Electric in Business Development (M&A) and Sponsor Leveraged Finance, covering sectors including healthcare. He holds an MBA from London Business School and an MA in Economics from the University of Edinburgh.

sronemedia@sambrown.com

Tanya McGlashan· Manager, UK Operations· Greater London, England, United Kingdomin

Tanya McGlashan joined SR One in October 2020, where she oversees risk, financial, and operational functions. Previously she worked at an investment bank managing data analytics projects and business support, and earlier held roles in accounts, compliance, and operations at a private equity and HNWI family office. She holds a BA in English and Spanish from N. Novgorod Linguistic University, a Diploma in Professional Accounting (AAT), and ACCA certificates in management accounts, performance management, taxation, and corporate/business law.

sronemedia@sambrown.com

Viraj Pillai· Finance Director· Londonin

Viraj Pillai is the Finance Director at SR One, based in the London office, where he oversees the fund's accounting, financial statements, and reporting, and works with external stakeholders and suppliers. He has over ten years of post-qualification experience, including five years with fund administrators and earlier work as an auditor at PwC (Sri Lanka/Botswana) and Deloitte UK. He holds a chartered accountancy qualification from the Institute of Chartered Accountants of Sri Lanka and is an associate member of the Institute of Certified Management Accountants.

Matthew Foy· Executive Officer

Dalton Stites· Executive Assistant· San Jose, California, United Statesin

Founder mafia

3 people who came through SR One Capital Management went on to found or lead other companies.

Matthew R. PattersonVenture PartnerFounded Audentes Therapeutics +2 Katarina PancePrincipalFounded Epi Biologics Rodger NovakVenture PartnerFounded CRISPR

What they invest in

from 54 of 76 portfolio companies

Biotech ×49Healthtech ×33Medical Devices ×12Deep Tech ×7AI & Machine Learning ×6Digital Health ×5Construction Tech ×1Enterprise Software ×1

HQs:United States×36United Kingdom×4Switzerland×1Denmark×1

Who they back

founder profiles across 23 portfolio companies

35%

solo founders

8 of 23 mapped founding teams

29%

repeat founders

of 17 founders with career history

~4 yrs

old at investment

median across 17 dated deals

Founding team size:solo founder×82 founders×103 founders×34+ founders×2

Where their founders studiedfrom 14 founders with education data

Massachusetts Institute of Technology ×3

What their founders studiedfrom 12 founders with field-of-study data

Life Sciences ×5Chemistry ×3Engineering ×2

Where their founders worked beforefrom 17 founders with career history

InterMune ×2Rigimmune ×2University of California, San Francisco ×2

Investments · 76 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 5 2024 · 3 2023 · 4 2022 · 4 2021 · 4 2020 · 6 2019 · 1 2018 · 1 2017 · 1 2016 · 5 2015 · 141 dated

Addex Therapeuticsaddextherapeutics.com in 𝕏NASDAQ: ADXNApr 2023SEC filingmedium confidence

Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.

BiotechHealthtechGeneva

Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)in Jean-Philippe Rocher(Executive Officer)in Robert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)

Board seat Jake Nunn· per SEC Form D · $3.7M raise · filed Apr 2023

Co-investorsNew Enterprise Associates (NEA)Sofinnova Partners ACORN BIOVENTURES

Veradermicsveradermics.com inNYSE: MANEOct 2025

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)in Tim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Board seat Katarina Pance· per SEC Form D

Co-investorsLongitude Capital Connecticut Innovations LifeSci Venture Partners OUP (Osage University Partners)abrdn plc Invus

Zenas Biopharmazenasbio.com inNASDAQ: ZBIOMay 2024

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in

Board PATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Board seat Jake Nunn· per SEC Form D

Co-investorsDelos Capital Longitude Capital New Enterprise Associates (NEA)Norwest Venture Partners Pivotal Life Sciences Quan Capital +3 more

Alumisalumis.com in 𝕏NASDAQ: ALMS

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)in Jack Danilkowicz(Chief Commercial Officer)in Jörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in

Co-investorsForesite Capital HBM Healthcare Investments HBM Partners Nextech Invest OrbiMed Samsara BioCapital +3 more

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNSeries C · Sep 2023 · $180M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners Pivotal Life Sciences +9 more

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCMay 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)in NIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Dementia Discovery Fund Longwood Fund Ridgeback Capital +4 more

Designtxdesigntx.com inNASDAQ: DSGNJan 2021

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical DevicesSolana Beach, US

Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)

BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)

Co-investorsAvoro Capital Advisors Quan Capital RA Capital Wellington Management WestRiver Group Quan Venture

KALA BIOkalarx.com inNASDAQ: KALA

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLongitude Capital Wellington Management Ysios Capital Atlas Venture Lux Capital RA Capital +1 more

Mineralys Therapeuticsmineralystx.com in 𝕏NASDAQ: MLYSJun 2022

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)in Alex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in

Co-investorsAndera Partners HBM Healthcare Investments HBM Partners Samsara BioCapital Ysios Capital Adams Street Partners +3 more

Nkarta, Inc.nkartatx.com inNASDAQ: NKTXAug 2019

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in

BoardMichael Dybbs(Director)Jill Carroll(Director)in Tiba Aynechi(Director)in

Co-investorsNew Enterprise Associates (NEA)RA Capital Samsara BioCapital Amgen Ventures Logos Norwest Venture Partners +1 more

Oruka Therapeutics Incorukatx.comNASDAQ: ORKA

Oruka is a biopharmaceutical company developing monoclonal antibody therapies aimed at treating plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions with fewer annual doses.

BiotechHealthtech

Lawrence Klein(Chief Executive Officer and Director)in

Co-investorsViking Global

Progynyprogyny.com in 𝕏NASDAQ: PGNYSeries B · Jul 2016 · $15M

Progyny provides employer-sponsored women's health and family-building benefits, covering preconception, fertility, pregnancy and postpartum, and menopause/midlife care through concierge support, digital tools, and a managed network of specialists.

Digital HealthFemTechHealthtechHR Tech

Gina Bartasi(Founder)inPeter Anevski(Chief Executive Officer and Director)

Co-investorsAurum Kleiner Perkins M Ventures Savano Capital Partners Union Grove Venture Partners

ADARx Pharmaceuticalsadarx.com inSeries B · Sep 2021 · $75M✓ verified

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Co-investorsBain Capital Life Sciences OrbiMed Lilly Asia Ventures T. Rowe Price Ascenta Capital TCG Crossover +3 more

Addition Therapeuticsadditiontx.com inDec 2025

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.

BiotechHealthtechSouth San Francisco, US

Kathleen Collins(Director)in Lawrence Kong(Executive Officer)in Ron Park(President & CEO)in Francine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in

Board Jayson Punwani(Director)in

Board seat Laetitia Schwab Matthew R. Patterson· per SEC Form D

Co-investorsBEVC Pivotal Life Sciences Abingworth Osage University Partners

ARS Pharmaceuticalsars-pharma.com in 𝕏Sep 2021 · $55M

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Board seat Rajeev Dadoo· per SEC Form D

Co-investorsNextech Invest OrbiMed RA Capital Sofinnova Ventures

CRISPRcrisprtx.com in 𝕏Oct 2016

CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

BiotechDeep TechHealthtechZug, CH

Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)in James R. Kasinger(General Counsel and Secretary)in Stephen Kennedy(Head of Technical Operations)in Megan Wherry Menner(Head of Human Resources)in Naimish Patel(Chief Medical Officer)in

Board seat Simeon J. George· per SEC Form D

Co-investorsAvoro Capital Advisors CLI Ventures Khosla Ventures New Enterprise Associates (NEA)Versant Ventures Wellington Management +3 more

Dermiradermira.comDec 2018SEC filingmedium confidence

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

Board Fred Craves(Director)in

Board seat Jake Nunn· per SEC Form D · $1M raise · filed Dec 2018

Co-investorsAisling Capital Bay City Capital Canaan Partners Foresite Capital New Enterprise Associates (NEA)Fidelity Investments +1 more

Dren Biodrenbio.comSeries A · Mar 2022 · $60M

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Founder)

BoardIvan Trifunovich(Director)John Wesley(Founder)

Board seat Rajeev Dadoo· per SEC Form D

Co-investors8VC Aisling Capital HBM Healthcare Investments HBM Partners Jacket River Capital Partners Mission Bay Capital +5 more

Navitor Pharmaceuticalsnavitorpharma.com inApr 2020SEC filingmedium confidence

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in

Board Jean-Francois Formela(Director)in Alan Crane(Director)in Marian Nakada(Director)in Brian Gallagher(Director)in

Board seat Rajeev Dadoo· per SEC Form D · $20.2M raise · filed May 2020

Co-investorsage1 Brace Pharma Sanofi Ventures Atlas Venture Polaris Partners

Odyssey Therapeuticsodysseytx.com in 𝕏Series A · Jun 2025 · $220M

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)

Board Carl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)

Board seat Jill Carroll· per SEC Form D

Co-investorsActivant Capital Ascenta Capital Balderton Capital Catalio Capital Management, LP Foresite Capital Global BioAccess Fund +9 more

Palleon Pharmaceuticalspalleonpharma.com in 𝕏Sep 2020

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical DevicesWaltham, US

Jim Broderick(Co-Founder)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)

Board seat Rajeev Dadoo· per SEC Form D

Co-investorsMatrix Capital Management Pfizer Ventures Pfizer Venture Investments BioHealth Innovation, Inc.Takeda Ventures Vertex Ventures HC

Regulus Therapeutics Inc.regulusrx.com in 𝕏Dec 2021acquired by Novartis · Apr 2025 · $1.7BSEC filingmedium confidence

Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.

BiotechHealthtechSan Diego, US

Neil Gibson(Executive Officer)Kleanthis Xanthopoulos(Executive Officer, Director)

BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)

Board seat Jake Nunn· per SEC Form D · $34.6M raise · filed Dec 2021

Co-investorsForesite Capital New Enterprise Associates (NEA)

Trivasculartrivascular.com in 𝕏Aug 2015acquired by EndologixSEC filingmedium confidence

Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures.

HardwareHealthtechMedical DevicesSanta Rosa, US

Michael V. Chobotov(Executive Officer)in SHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VIVEK K. JAYARAMAN(Executive Officer)in

Board seat Jake Nunn· per SEC Form D · $10M raise · filed Aug 2015

Co-investors415 Capital Kaiser Permanente Ventures New Enterprise Associates (NEA)Deerfield Management Company

4646.capitalJan 2023 · $46M

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHurricane Ventures Andreessen Horowitz Ascenta Capital Avaana Capital BoxGroup Claypond Capital +7 more

AirNexis Therapeuticsairnexis.com inSeries A · Jan 2026 · $200M

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

BiotechPalo Alto, US

James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in

BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in

Co-investorsFrazier Life Sciences Longitude Capital OrbiMed

Akamis Bioakamisbio.com in 𝕏

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsARCH Venture Partners IP Group Lundbeckfonden Ventures Westlake Village BioPartners

Ancora Biotechancorabiotech.com in

Ancora Biotech is a privately held biotherapeutics developer overseeing the manufacturing and clinical development of three multi-specific antibodies held in separate spin-offs.

BiotechHealthtech

Co-investorsLightspeed Venture Partners Sutter Hill Ventures

Antag Therapeuticsantagtherapeutics.com in

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in

Co-investorsBroadview Ventures Novo Holdings Versant Ventures

Arcellxarcellx.com in

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in

Board Jill Carroll(Director)in Ali Behbahani(Director)in Derek Yoon(Director)in Tiba Aynechi(Director)in

Co-investorsLG Technology Ventures New Enterprise Associates (NEA)Quan Capital Samsara BioCapital Sixty Degree Capital Solasta Ventures +5 more

Arch Oncology Incarchoncology.comSeries A · Aug 2016 · $86M

Co-investorsAvego BioScience Capital BioGenerator Ventures Perot Jain RiverVest Venture Partners Roche Venture Fund

Asceneuronasceneuron.com in 𝕏

Biotech

Co-investorsKurma Partners Sofinnova Partners Johnson & Johnson Innovation – JJDC M Ventures EQT Life Sciences

Avenzoavenzotx.com inSep 2025 · $60M

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

BiotechSan Diego, US

Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in

BoardCarl Gordon(Director)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed +6 more

Biotheryxbiotheryx.com in

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))in Raymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsLumira Ventures Revelation Partners

CHARM Therapeuticscharmtx.com in

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)David Baker(Founder)Laksh Aithani(Founder)

Board Rishi Gupta(Director)in Nihal Sinha(Director)in Muzammil Mansuri(Director)in

Co-investorsF-Prime Capital New Enterprise Associates (NEA)OrbiMed Axial VC Khosla Ventures NVentures

Codify Therapeuticscodifytx.com in

Codify Therapeutics is a discovery-stage biotech developing cancer therapeutics that target abnormal alternative RNA splicing, such as in splicing-factor-mutant leukemias.

Draig Therapeuticsdraigtherapeutics.com in

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)in Simon Ward(Chief Scientific Officer & Founder)in

Co-investorsAccess Biotechnology Canaan Partners Sanofi Ventures SV Health Investors British Business Bank Janus Henderson Investors

Econic Bioscienceseconicbio.com in

Econic Biosciences is a biotech company developing cancer therapies that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification and tumor evolution.

BiotechDeep TechHealthtechLondon, GB

Ralph Lindemann(Chief Scientific Officer)Pete Johnson(Head of Medicinal Chemistry)Steven Whittaker(Head of Biology)inAlastair Hamilton(Head of Business Operations & Strategy)in

BoardRodger Novak(Executive Chairman)in

Fore Biotherapeuticsfore.bio in 𝕏May 2025 · $40M

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBM Healthcare Investments HBM Partners LG Technology Ventures Novartis Venture Fund OrbiMed Pontifax Venture Capital +4 more

HotSpot Therapeuticshotspotthera.com in 𝕏Series B · May 2020 · $65M

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

Board Bruce Booth(Chairman)in

Co-investorsAtlas Venture B Capital Group B4 Capital MRL Ventures Fund Pivotal Life Sciences Sofinnova Partners +2 more

IlluminOss Medical inSeries C · Sep 2012 · $28M

BiotechEast Providence, US

Manny Avila(Executive Officer, Director)in Dirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)

BoardDaniel Omstead(Director)Fouad Azzam(Director)inRajeev Dadoo(Director)

Co-investorsPappas Capital Life Sciences Partners

Immutrinimmutrin.com in

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.

BiotechMedical Devices

Mark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)Gregory Winter(Co-founder; Nobel Laureate)Daniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)

Co-investorsCambridge Innovation Capital Frazier Life Sciences Qiming Venture Partners F-Prime Capital

Kartostherakartosthera.com in 𝕏

Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers.

BiotechHealthtech

Co-investorsOrbiMed

Mission Therapeuticsmissiontherapeutics.com in 𝕏

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsPfizer Venture Investments Roche Venture Fund Rosetta Capital Ltd.Sofinnova Partners IP Group

Nimbus Therapeuticsnimbustx.com inSep 2023 · $210M

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Dementia Discovery Fund GV (Google Ventures)Lightstone Ventures+4 more

Nomicnomic.ai in 𝕏

Nomic is an AI platform for architecture, engineering, and construction (AEC) teams that orchestrates agents across drawings, specs, submittals, RFIs, and building codes to automate coordination and review work.

AI & Machine LearningConstruction TechEnterprise Software

Brandon Duderstadt(Founder)inAndriy Mulyar(Founder)Ben Schmidt(Founder)

Co-investorsBetaworks Coatue Management Contrary 2048 Ventures Dynamk Capital Lux Capital

Pandion Therapeuticspandiontx.comacquired by Merck · Feb 2021 · $1.9B

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)in Anthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Co-investorsAccess Biotechnology JDRF T1D Fund Mission Biocapital RA Capital Polaris Partners Versant Ventures

Poplar Therapeuticspoplartx.comSeries A · Jan 2026 · $50M

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

Biotech

Co-investorsRA Capital Vida Ventures

Principia Biopharmaprincipiabio.comSeries A · Oct 2012 · $13M

BiotechSouth San Francisco, US

MARTIN BABLER(Executive Officer, Director)in

Board PETER THOMPSON(Director)in SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsAccess Biotechnology Mission Biocapital Sofinnova Ventures Mission Bay Capital New Leaf Venture Partners OrbiMed +1 more

Pulmocidepulmocide.com in

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant Capital Asahi Kasei Corporate Venture Capital Dementia Discovery Fund F-Prime Capital Jeito Capital Longwood Fund +4 more

Rezo Therapeuticsrezotx.com inSeries A · Nov 2022 · $78M

Rezo maps disease networks to find insights into disease biology for drug discovery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Nevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)

Co-investorsAndreessen Horowitz Norwest Venture Partners HAWKTAIL Valkyrie Ventures Management, Llc ARCH Venture Partners SV Angel

Second Genomesecondgenome.comSeries B · Apr 2016 · $51M

Co-investorsLifeforce Capital Pfizer Venture Investments Digitalis Ventures Lightstone Ventures Morgenthaler Roche Venture Fund

Simcha Therapeuticssimchatx.com inSeries B · Jan 2022 · $40M

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)in Beatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut Innovations Pfizer Venture Investments Axial VC Biotechnology Value Fund Rock Springs Capital Samsara BioCapital

Telios Pharmateliospharma.com

Telios Pharma is a clinical-stage biopharmaceutical company developing first-in-class topical and oral BTK-inhibitor drugs targeting mast-cell-mediated inflammation, including TL-925 for dry eye disease.

Topo Therapeuticstopo-tx.com

Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.

BiotechHealthtechCambridge, US

Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)

Board Karin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)

Co-investorsMRL Ventures Fund The Column Group

Tranquis Therapeuticstranquis.comSeries A · Jul 2020 · $30M

Co-investorsVivo Capital Remiges Ventures, Inc.

Turning Point Therapeuticstptherapeutics.comSeries C · May 2017 · $45M

Co-investorsForesite Capital LAV Lilly Asia Ventures Nextech Invest Sv Tech Ventures, Inc.HBM Partners

Windward Biowindwardbio.com in

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMed Quan Capital RA Capital Sanofi Ventures Janus Henderson Investors Novo Holdings +3 more

Xap Therapeuticsxaptherapeutics.com in

Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition.

BiotechDeep TechCambridge, GB

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Bird Rock Bio Entasis Therapeutics Holdings Alios BiopharmaARS PharmaCorxel Pharmaceuticals LimitedCrystalys Therapeutics, Inc.Decibel TherapeuticsDesign TherapeuticsElektrofi, Inc.iPierianMorphic TherapeuticNimbusRenalysRenalys PharmaRiver RenalRiver VisionTrue North TherapeuticsVibrant Biomedicines

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 18

12 IPOs · 6 acquisitions

Addex TherapeuticsNASDAQ: ADXNVeradermicsNYSE: MANEZenas BiopharmaNASDAQ: ZBIOAlumisNASDAQ: ALMSAvalyn Pharma IncNASDAQ: AVLNBicycleNASDAQ: BCYCDesigntxNASDAQ: DSGNKALA BIONASDAQ: KALAMineralys TherapeuticsNASDAQ: MLYSNkarta, Inc.NASDAQ: NKTXOruka Therapeutics IncNASDAQ: ORKAProgynyNASDAQ: PGNYBird Rock Bioacq. by Skye BioscienceRegulus Therapeutics Inc.acq. by NovartisTrivascularacq. by EndologixDecibel Therapeuticsacq. by RegeneronPandion Therapeuticsacq. by MerckRenalysacq. by Chugai Pharmaceutical Co., Ltd.

Portfolio news

latest coverage across their companies

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - BioSpace

Designtx · biospace.com · Aug 3, 2026

Draig Therapeutics Raises $65M in Series B Funding

Draig Therapeutics · finsmes.com · Jul 14, 2026

FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding

Fore Biotherapeutics · finsmes.com · Jul 8, 2026

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer

Antag Therapeutics · globenewswire.com · May 21, 2026

Windward Bio Raises $165M in Crossover Funding

Windward Bio · finsmes.com · May 5, 2026

Dren Bio - BioSpace

Dren Bio · biospace.com · Mar 2, 2026

Addition Therapeutics Raises $100M in Funding

Addition Therapeutics · finsmes.com · Dec 17, 2025

Mission Therapeutics Raises $13.3M in Funding

Mission Therapeutics · finsmes.com · Oct 15, 2025

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
SR One Capital Fund II-A, LPLPs: California Public Employees' Retirement System	2023	—	—	0.89x	0.04x
SR One Capital Opportunities Fund I, LPLPs: California Public Employees' Retirement System	2023	—	—	0.63x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Avalyn Pharma Inc	6.6%	$18.00	Apr 2026	$49.6M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has SR One Capital Management made?: SR One Capital Management has 76 tracked investments, 18 of which have exited, including 7 dated in the last 24 months.
What stage does SR One Capital Management invest at?: SR One Capital Management invests at the Seed, Series A, Series B stages.
What sectors does SR One Capital Management focus on?: SR One Capital Management focuses on Biotech, Healthtech, Medical Devices.
Where is SR One Capital Management located?: SR One Capital Management is headquartered in Redwood City, US.
Who does SR One Capital Management co-invest with?: SR One Capital Management most often shares deals with OrbiMed, RA Capital, New Enterprise Associates (NEA), among 100 tracked co-investors.
What size deals does SR One Capital Management back?: Across 16 deals with disclosed amounts, SR One Capital Management has joined rounds of $13M – $220M (median $57.5M).

Co-investors · 42

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 12

Alumis 46 ADARx Pharmaceuticals AirNexis Therapeutics ARS Pharmaceuticals Avenzo CHARM Therapeutics Fore Biotherapeutics Kartosthera Odyssey Therapeutics Principia Biopharma Windward Bio

$1M – $75M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 10

Addex Therapeutics Nkarta, Inc.Zenas Biopharma Arcellx Avenzo CHARM Therapeutics CRISPR Dermira Regulus Therapeutics Inc.Trivascular

$200K – $40M

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 10

Designtx KALA BIO Mineralys Therapeutics Nkarta, Inc.ARS Pharmaceuticals Pandion Therapeutics Poplar Therapeutics Windward BioDesign TherapeuticsNimbus Therapeutics

Samsara BioCapital

Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.

Both backed · 7

Alumis Mineralys Therapeutics Nkarta, Inc.Arcellx Principia Biopharma Simcha TherapeuticsDecibel Therapeutics

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 6

Mission Therapeutics Palleon Pharmaceuticals Simcha TherapeuticsMorphic TherapeuticNimbus TherapeuticsSecond Genome

$5M – $20M

HBM Partners

HBM Partners is a Swiss healthcare-focused asset manager that invests in private and public companies across biopharma, medtech, diagnostics and healthcare, supporting portfolio companies through all stages of development.

Both backed · 6

Alumis Mineralys Therapeutics Dren Bio Fore BiotherapeuticsRiver RenalTurning Point Therapeutics

$5M – $50M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 5

Bicycle KALA BIO HotSpot Therapeutics Navitor PharmaceuticalsNimbus Therapeutics

$500K – $1M

Pivotal Life Sciences

Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.

Both backed · 5

Avalyn Pharma Inc Zenas Biopharma Addition Therapeutics HotSpot Therapeutics Windward Bio

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 4

Addex Therapeutics HotSpot Therapeutics Mission TherapeuticsAsceneuron

$540K – $27M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 4

ARS Pharmaceuticals Avenzo Principia BiopharmaElektrofi, Inc.

$100K – $15M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 4

Alios Biopharma Mission TherapeuticsArch Oncology IncSecond Genome

$648K – $3.2M

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Both backed · 4

46 ADARx Pharmaceuticals AvenzoTurning Point Therapeutics

▶30 more co-investors

ARCH Venture Partners Versant Ventures Andreessen Horowitz GV (Google Ventures)Kleiner Perkins B Capital Group Canaan Partners Polaris Partners Johnson & Johnson Innovation – JJDC Third Rock Ventures Abingworth Novartis Venture Fund Aisling Capital Lightstone Ventures RiverVest Venture Partners General Catalyst EQT Life Sciences OUP (Osage University Partners)5AM Ventures The Column Group Morgenthaler Kurma Partners Remiges Ventures, Inc.Venrock Highbury Holdings MPM BioImpact Stanford University Advent Life Sciences Dolby Family Ventures 3B Future Health Fund

Firms observed investing alongside SR One Capital Management, from public investor directories. Shared companies are the overlap with SR One Capital Management's recorded portfolio.

Similar investors

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

$500K – $15M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

$500K – $10M

Black Opal Ventures

Black Opal Ventures is a venture capital firm founded in 2021 by Tara Bishop and Eileen Tanghal, investing at the intersection of technology and healthcare.

Frist Cressey Ventures

Frist Cressey Ventures (FCV) is a venture capital firm focused on transforming healthcare and improving lives, offering portfolio companies strategic support alongside capital.

$500K – $20M

Sandbox Industries

Sandbox Industries is an investment firm that fosters innovation in the healthcare and insurance industries, partnering with corporate strategic investors as limited partners alongside financial investors and portfolio companies.